Upperton has formally submitted its application to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for approval of its 7,000 sq. ft sterile manufacturing facility. This submission follows the successful completion of aseptic process simulation (APS) validation batches executed under the stringent requirements of the revised EU GMP Annex
Nottingham, UK. September 15th 2025 – Upperton Pharma Solutions has added another impressive award to a growing list of achievements, winning the award for Pharma Contract Services Company of the Year at the Pharma Industry Awards UK 2025 and being nominated as a finalist for Pharma Company of the Year.
Nottingham, UK. August 14th 2025 – Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford. The funding supports the development of an oral formulation for
Nottingham, UK. July 7th 2025 – Upperton Pharma Solutions, a leading Nottingham-based pharmaceutical contract development and manufacturing organisation (CDMO), is delighted to announce its recognition as the winner of the Business Expansion award in the Integrated Manufacturing category at the 2025 Pharmaceutical Technology Excellence Awards. Powered by the global insights
NOTTINGHAM, UK. January 28th, 2025 – Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing facility in Nottingham, UK. The new facility is in addition to its existing 50,000 sq. ft facility, Trent Gateway, and the purpose-built facility has
NOTTINGHAM, UK. September 24th, 2024 – Upperton Pharma Solutions has been awarded Pharma Project of the Year at the Pharma Industry Awards UK 2024, held at the International Convention Centre (ICC) in Birmingham on Wednesday, 18th September. The prestigious event celebrated excellence across the pharmaceutical and biotech sectors, recognising achievements
NOTTINGHAM, UK. July 16th, 2024 – Upperton Pharma Solutions, a contract development and manufacturing organisation (CDMO), is pleased to announce the successful completion of a Medicines and Healthcare products Regulatory Agency (MHRA) inspection at its newly commissioned 50,000 sq ft development and GMP manufacturing facility in Nottingham, UK. This milestone
NOTTINGHAM, UK, 22 March 2024 – UK-based contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and local leaders to celebrate the official opening of a new 50,000 square foot development and GMP manufacturing facility in
NOTTINGHAM, UK, 16th January 2024 – Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) has announced a £5 million investment to expand operations into small-scale sterile fill-finish. After completing the build and qualification of a new 50,000 sqft GMP facility during 2023, the UK-based CDMO announces